

Supplementary Table S1. Clinical trials related to cannabinoid use in cancer (source clinicaltrials.gov as of 06.22.2022).

Official title	Condition or disease	Comparison group/Cohort	Outcome	Identifier
Palliative care				
Inhaled PPP001 Versus Immediate-release Oral Opioids for the Management of Breakthrough Pain in Cancer Subjects: a Randomized, Open-Label, Crossover, Comparison Study	Cancer Breakthrough Cancer Pain	Experimental Drug: PPP001 (inhaled cannabinoids) Active Comparator: Morphine sulfate or Hydromorphone or Oxycodone	Recruiting	NCT03564548
Safety And Efficacy Of Ppp001-kit For The Uncontrolled Pain Relief In Patients With Advanced Cancer: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study	Cancer Pain Quality of Life Pain, Acute Cannabis Use	Drug: PPP001 (cannabis dosing capsule with THC/CBD) inhalation with a device Drug: Placebo	Recruiting	NCT04042545
Patient Reported Symptom Control With THC and CBD Use	Cancer-associated Pain Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm	Electronic Health Record Review Questionnaire Administration	Recruiting	NCT04875286
Quantification of Endo- and Phytocannabinoids With Comparison to Pain Medication Requirements and Surgical Outcomes for Patients Undergoing Abdominal Surgery for Cancer	Post-Surgical Pain Post-surgical complication Cancer Cannabis use	Daily cannabis users Cannabis non-users	Recruiting	NCT04988490
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-Related Symptoms in Patients With Locally Advanced or Metastatic Pancreatic Cancer During First-line Chemotherapy (DIsCOvER)	Pancreatic Cancer Non-resectable Chemotherapy-induced Nausea and Vomiting Pancreatic Cancer Metastatic	Drug: Dronabinol in Oral Dosage Form Drug: Placebo	Recruiting	NCT03984214

Treatment of Established Chemotherapy-Induced Neuropathy With N-Palmitoylethanolamide, a Cannabimimetic Nutraceutical: A Randomized Double-Blind Phase II Pilot Trial	Chemotherapy-Induced Peripheral Neuropathy Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm	Drug: Palmidrol Drug: Placebo Administration Other: Quality-of-Life Assessment	Recruiting	NCT05246670
NanaBis™ an Oro-buccal Administered Equimolar delta-9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial	Cancer-related pain	Drug: NanaBis™ Drug: Oxycodone CR Drug: Placebo Spray Drug: Placebo Tablet Drug: Oxycodone IR	Not yet recruiting	NCT04808531
Pharmacokinetic and Pharmacodynamic Evaluation of 3 Standard Formulations of Δ9-THC in Healthy Volunteers and Post-chemotherapy Patients in Colombia	Nausea Post-Chemotherapy Vomiting Cancer Pain Cancer-Related Pain Neoplasm	Drug: Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator	Not yet recruiting	NCT05272865
A Randomized, Double-Blind, Placebo-Controlled, Multiple Crossover N-of-1 Study Design of the Use of Medicinal Cannabis Oil-Based Extracts for Symptom Management in Cancer Patients	Pain Nausea Anxiety Sleep Disturbance	Drug: Cannabis	Active, not recruiting	NCT03948074
A Double-blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study	Cancer Anorexia Taste Disorders Olfactory Disorders	Drug: Marinol (Dronabinol) Marinol is being used as an appetite stimulant for treatment of cancer-induced anorexia	Completed (no results)	NCT00316563
A Pilot Trial to Evaluate Syndros in Decreasing Opioid Requirement in Patients With Bone Metastases From Breast Cancer	Bone Metastases Breast Cancer Pain	Drug: Syndros (Dronabinol)	Completed (no results)	NCT03661892
A Double Blind, Randomized, Placebo Controlled, Parallel Group Dose-range Exploration	Palliative Care Pain Cancer	Drug: Sativex Low Dose Drug: Sativex Medium Dose	No baseline differences	NCT00530764

Study of Sativex® in Relieving Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy		Drug: Sativex High Dose	across the groups. Demonstrated efficacy and safety in low- and medium doses (238)	
Randomized, Double-Blind, Placebo-Controlled Trial of Palonosetron/Dexamethasone With or Without Dronabinol for the Prevention of Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy	Chemotherapy-induced Nausea and Vomiting Unspecified Adult Solid Tumor	Arm 1 Drug: Dexamethasone Drug: Dronabinol Drug: Palonosetron Hydrochloride Arm 2 Drug: Dexamethasone Drug: Palonosetron Hydrochloride Drug: Placebo	Completed (no publications)	NCT00553059
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex Oromucosal Spray (Sativex; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer-Related Pain	Pain Advanced Cancer	Drug: Nabiximols	Completed (no publications)	NCT01337089
A Double Blind, Randomized, Parallel Group, Placebo Controlled, Comparative Study of the Efficacy, Safety and Tolerability of Cannabis Based Medicine (CBM) Extracts in Patients With Cancer-related Pain	Palliative care Pain Cancer	Drug: Placebo Drug: Sativex Drug: THC Alone	The mean pain Numerical Rating Scale score was statistically significant for THC/CBD group in pain reduction (239)	NCT00674609
An Open-label, Extension Study, to Investigate the Long-term Safety and Tolerability of Cannabis Based Medicine Extracts in Patients With Cancer-related Pain	Pain Cancer	Drug: Sativex Drug: GW-2000-02 (THC alone)	In mean Brief Pain Inventory-Short Form Scores for "pain severity" and "worst pain" showed an	NCT00675948

			improvement in the THC/CBD spray patients(240)	
The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer	Neoplasms Pancreatic Cachexia Cancer Cannabis Appetite Loss Palliative Medicine Morbidity Mortality	Drug: THC and CBD	Unknown	NCT03245658
Cancer treatment				
Effects of Cannabis Use in Cancer Patients: A Feasibility Study	Solid Tumor Adult	Oral Cannabis	Recruiting	NCT03617692
A Pilot Study to Assess the Role of Cannabis Added to the Supportive Care Regimen During Chemoradiation for Head and Neck Cancer	Head and Neck Cancer	Observational group using THC/CBD formulations	Recruiting	NCT03431363
Outcomes Mandate National Integration With Cannabis as Medicine (200,000 participants)	Chronic Pain Fibromyalgia Seizures Hepatitis Cancer Crohn Disease HIV/AIDS Multiple Sclerosis Traumatic Brain Injury Sickle Cell Disease Post-Traumatic Stress Disorder Tourette Syndrome Ulcerative Colitis Glaucoma Epilepsy Inflammatory Bowel Diseases Parkinson Disease Amyotrophic Lateral Sclerosis Chronic Traumatic Encephalopathy Anxiety Depression Insomnia	Drug: Cannabis, Medical Device: RYAH-Medtech Inhaler	Recruiting	NCT03944447

	Autism Opioid-use Disorder Bipolar Disorder Covid			
Medical Marijuana in the Pediatric Central Nervous System Tumor Population	Central Nervous System Tumor Brain Tumor Spinal Tumor	Drug: Medical Marijuana	Active, not recruiting	NCT03052738
Phase Ib, Open-label, Multicenter, Inpatient Dose-escalation Clinical Trial to Assess the Safety Profile of the TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma	Glioblastoma	Drug: TN-TC11G Drug: Temozolomide Radiation: Radiotherapy	Not yet recruiting	NCT03529448
Expression of G Protein-coupled Receptors and Ligands in Inflammatory Bowel Diseases and Colon Cancer	Ulcerative colitis Crohn's Disease Colon Cancer	Ulcerative colitis group Crohn's Disease group Colon Cancer group Control group (healthy individuals)	Completed (no results)	NCT02735941
A Phase I, Sequential Cohort, Open-Label, Dose-escalation Study of the Safety and CNS Pharmacokinetics of Dexanabinol in Patients With Brain Cancer	Brain cancer	Drug: Dexanabinol	Completed (no results)	NCT01654497
A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas	Brain Neoplasms Nausea Vomiting	Drug: Dronabinol	Completed (no publications)	NCT00314808
A Phase 1, Pharmacokinetically-Guided, Dose Escalation Study to Assess the Safety and Tolerability of Dexanabinol in Patients With Advanced Solid Tumors	Solid Tumor	Drug: Dexanabinol Other: Cremophor	Progression-free survival increased	NCT01489826
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma	Glioblastoma multiforme	Drug: Temozolomide and Sativex	Increased 1-year survival rate in 39% (185)	NCT01812603; NCT01812616
A study: Pure CBD as single agent for solid tumors	Solid tumor	Drug: CBD	(241)	NCT02255292
A Phase 1b Study to Assess the Safety and Anti-tumour Activity of Dexanabinol Monotherapy and	Hepatocellular carcinoma Pancreatic cancer	Drug: Dexanabinol Drug: Sorafenib Drug: Nab-paclitaxel	Unknown	NCT02423239

Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours		Drug: Gemcitabine		
A Phase I Study of BRCX014 to Investigate Dose-Ranging Safety and Pharmacokinetics in Adults With Glioblastoma (GBM) and Non-Methylated MGMT Gene Status	Glioblastoma	Drug: Temozolomide Drug: BRCX014 (cannabinoid formulation)	Unknown	NCT03687034
Randomized Double-Blind, Placebo-Controlled Parallel Multi-Center Study to Assess the Efficacy of Cannabidiol (BRCX014) Combined With Standard-Of-Care Treatment in Subjects With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies	Cancer of Pancreas Cancer of Liver Cancer of Rectum Cancer of Colon Gall Bladder Cancer Multiple Myeloma Glioblastoma Multiforme	Drug: Cannabidiol Drug: Bortezomib Drug: Leucovorin Drug: 5-FU Drug: Oxaliplatin Drug: Bevacizumab Drug: Irinotecan Drug: Gemcitabine Drug: Temozolomide	Unknown	NCT03607643
Safety				
Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects	Safety Tolerability Pharmacokinetics Cancer	Drug: Dexanabinol Dose Level 1 Drug: Dexanabinol Dose Level 2 Drug: Dexanabinol Dose Level 3 Drug: Dexanabinol Dose Level 4 Drug: Dexanabinol Dose Level 5 Drug: Placebo	Completed (no publications)	NCT02054754
An Observational Post-Marketing Safety Registry Of Patients Who Have Been Prescribed Sativex	Multiple Sclerosis Diabetes Cancer Neuropathic Pain	Drug: Sativex	Completed (no results)	NCT02073474